Surprise at the last technical meeting of the European Medicines Agency. Despite expecting news regarding the two vaccines closest to approval for the new vaccination campaign, Sanofi and Hipra, the Agency has reported that a new serum, which until now was not part of the European radar, has been cast in the race to obtain the authorization of continental commercialization.
The Korean company SK Chemicals has placed its serum, commercially called Skycovion, on the exit ramp to get the technical yes from the agency. The serum has the same technology as its competitors, so it represents some serious competition. , which means that it could only reach the market by negotiating with each Member State if it gets authorization.
The European Medicines Agency explains that in future meetings it will report on the technical analysis of the safety and efficacy data that the Korean company has sent to the technicians of the regulatory body. If the expected schedules do not change, and with this new addition, there may be three new protein-based vaccines in September that compete with Pfizer and Moderna.
These two American companies have been working for the past few months to adapt their serum to the latest variant of concern, omicron. Two days ago, Moderna already got the yes from the British authorities and now it is expected that the EMA will also issue the opinion.
The question that is still in the air is which will be the ideal among all the candidates to be used as a booster vaccine. Today, what it is about discerning is what type of pattern seeks the highest rate of antibodies to fight the coronavirus.
Facebook Comments
Disqus